A strong positive correlation was observed between tumor uptake (SUVpeak) and PD-L1 immunohistochemistry (r = 0.9349; P = 0.002), which suggesting that PD-L1 PET could help predict the response to pembrolizumab in combination with chemotherapy. The gene discussed is CD274; the disease is neoplasm.